Critical Therapeutics of Lexington, Massachusetts, plans to raise $54.5 million in a private stock sale with a part of the funds going to relaunch its Zyflo asthma drug, acquired from Abbott last year. The launch is expected in the second half of this year. Other funds will go to advance its pipeline drugs.
- read this story from the AP for more